Bionano Genomics Company Leadership
| BNGO Stock | USD 0.24 0.01 4.00% |
About 80 percent of all Bionano Genomics' insiders are aggressively buying. The analysis of insiders' sentiment of trading Bionano Genomics stock suggests that quite a few insiders are very bullish at this time. Bionano Genomics employs about 344 people. The company is managed by 15 executives with a total tenure of roughly 803 years, averaging almost 53.0 years of service per executive, having 22.93 employees per reported executive.
Bionano Genomics' Insider Buying Vs Selling
80
Selling | Buying |
Latest Trades
| 2023-06-13 | Hannah Mamuszka | Acquired 6578 @ 7.6 | View | ||
| 2023-05-16 | R. Erik Holmlin | Acquired 1500 @ 6.4 | View | ||
| 2023-05-12 | Christopher P Stewart | Acquired 5000 @ 6.7 | View | ||
| 2022-08-15 | Yvonne Linney | Disposed 2000 @ 36.2 | View | ||
| 2021-11-29 | R. Erik Holmlin | Acquired 502 @ 39.9 | View |
Monitoring Bionano Genomics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Bionano |
Bionano Genomics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3264) % which means that it has lost $0.3264 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3833) %, meaning that it created substantial loss on money invested by shareholders. Bionano Genomics' management efficiency ratios could be used to measure how well Bionano Genomics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -1.35. In addition to that, Return On Capital Employed is likely to drop to -1.98. At this time, Bionano Genomics' Net Tangible Assets are very stable compared to the past year. As of the 29th of November 2024, Non Currrent Assets Other is likely to grow to about 7.8 M, while Total Assets are likely to drop about 142.9 M.As of the 29th of November 2024, Common Stock Shares Outstanding is likely to grow to about 35.9 M, though Net Loss is likely to grow to (113.4 M).
Bionano Genomics Workforce Comparison
Bionano Genomics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 109,467. Bionano Genomics adds roughly 344 in number of employees claiming only tiny portion of equities under Health Care industry.
Bionano Genomics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bionano Genomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bionano Genomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bionano Genomics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kama Gulsen over a month ago Acquisition by Kama Gulsen of 16000 shares of Bionano Genomics subject to Rule 16b-3 | ||
Adamchak Mark over a month ago Acquisition by Adamchak Mark of 17500 shares of Bionano Genomics at 0.42 subject to Rule 16b-3 | ||
Linney Yvonne over two months ago Acquisition by Linney Yvonne of 30000 shares of Bionano Genomics at 0.7752 subject to Rule 16b-3 | ||
Adamchak Mark over two months ago Insider Trading | ||
Christopher Stewart over two months ago Acquisition by Christopher Stewart of 22500 shares of Bionano Genomics at 0.56 subject to Rule 16b-3 | ||
Chaubey Alka over two months ago Disposition of 3075 shares by Chaubey Alka of Bionano Genomics at 0.48 subject to Rule 16b-3 | ||
Chaubey Alka over three months ago Acquisition by Chaubey Alka of 16000 shares of Bionano Genomics subject to Rule 16b-3 | ||
Linney Yvonne over six months ago Disposition of 20000 shares by Linney Yvonne of Bionano Genomics at 0.38 subject to Rule 16b-3 |
Bionano Genomics Notable Stakeholders
A Bionano Genomics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bionano Genomics often face trade-offs trying to please all of them. Bionano Genomics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bionano Genomics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jonathan JD | General Secretary | Profile | |
| Donna Polizio | Global Access | Profile | |
| Klint Rose | Head Development | Profile | |
| Helene Klein | Chief Officer | Profile | |
| Sheila MBA | Vice Marketing | Profile | |
| Christopher Stewart | Chief Officer | Profile | |
| Jonathan Dixon | Global Legal | Profile | |
| Gulsen MBA | Chief Officer | Profile | |
| Cory Kreeck | Global Operations | Profile | |
| Alka FACMG | Chief Officer | Profile | |
| Mark CPA | VP Controller | Profile | |
| MS MBA | Head Sales | Profile | |
| Mark Oldakowski | Chief Officer | Profile | |
| Robert MBA | CEO and President | Profile | |
| Soheil Shams | CIO Emeritus | Profile |
About Bionano Genomics Management Performance
The success or failure of an entity such as Bionano Genomics often depends on how effective the management is. Bionano Genomics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bionano management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bionano management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.29) | (1.35) | |
| Return On Capital Employed | (1.88) | (1.98) | |
| Return On Assets | (1.08) | (1.14) | |
| Return On Equity | (2.42) | (2.54) |
Bionano Genomics Workforce Analysis
Traditionally, organizations such as Bionano Genomics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bionano Genomics within its industry.Bionano Genomics Manpower Efficiency
Return on Bionano Genomics Manpower
| Revenue Per Employee | 105K | |
| Revenue Per Executive | 2.4M | |
| Net Loss Per Employee | 675.9K | |
| Net Loss Per Executive | 15.5M | |
| Working Capital Per Employee | 116.5K | |
| Working Capital Per Executive | 2.7M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.30) | Revenue Per Share 0.749 | Quarterly Revenue Growth (0.10) | Return On Assets (0.33) | Return On Equity (1.38) |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.